Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy

Wei Feng1,2, Zhan Qi3, Rong Qiu4, Zhen-Sheng Li4, Shi-Lei Dong4,5, Yue-Kao Li6, Yuan-Ping Hu4, Ming He3 and Yu-Xiang Wang4

Abstract
Objective: To analyze the factors contributing to recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma (ESCC).
Methods: Patients with pT3N0M0 thoracic ESCC who underwent esophagectomy from January 2008 to December 2012 were included retrospectively. The last date of follow-up was 1 December 2016. Multivariate proportional hazard Cox models were used to identify factors associated with total (i.e., any) recurrence (TR), locoregional recurrence (LR), and distant metastasis (DM).
Results: A total of 692 patients were included. The median follow-up was 53 months (range: 3–107). The 3- and 5-year TR, LR, and DM rates were 35.8% and 41.0%, 28.7% and 32.1%, and 16.8% and 21.1%, respectively. The Cox analyses showed that the tumor location, number of dissected lymph nodes, and postoperative therapies were significantly associated with LR. The subgroup analysis showed that postoperative therapies could significantly decrease LR in the mediastinum but not in the neck and upper abdomen regions.

1Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China
2Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China
3Department of thoracic surgery, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China
4Department of Radiation Oncology, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China
5Department of Radiation Oncology, Hebei University Affiliated hospital, Baoding, China
6Department of CT/MRI, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China

Corresponding author:
Yuxiang Wang, Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, No. 12, Jiankang road, Shijiazhuang, Hebei Province 050011, China.
Email: wyxhs69@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Conclusions: The recurrence rate of pT3N0M0 thoracic ESCC patients was high, especially for LR in the mediastinum. Postoperative therapies can significantly reduce the incidence of mediastinal recurrence.

Keywords
Esophageal squamous cell carcinoma, esophagectomy, recurrence, adjuvant radiotherapy, adjuvant chemotherapy, distant metastasis

Date received: 14 July 2020; accepted: 6 November 2020

Introduction
Esophageal cancer (EC) is the seventh most common cancer worldwide.1 The incidence of EC is higher in developing countries than in developed ones.2 Over half of newly diagnosed EC cases occur in China.3 Esophageal squamous cell carcinoma (ESCC) has remained the predominant pathological type of EC in China, accounting for over 90% of EC patients.4 Neoadjuvant chemoradiotherapy (NCRT) is recommended by the National Comprehensive Cancer Network (NCCN) for esophageal carcinoma in patients with node-positive disease and bulky tumors based on the results of many large scale studies, such as the CROSS trial.5 A network meta-analysis by Huang Y et al. also confirmed that NCRT could increase the radical resection rate and lower the occurrence of complications, thereby prolonging the survival time for ESCC patients.6 However, in China, radical esophagectomy is regarded as a curative treatment for resectable ESCC (e.g., pT1–3N0).

After surgery, many patients develop locoregional recurrence (LR) and distant metastasis (DM).7–11 The reported 5-year survival rates of pT1–3N0 ESCC patients after radical esophagectomy in China is ~50%.12–14 Postoperative radiotherapy (PORT) and chemotherapy (POCT) have been shown to improve the survival of locally advanced ESCC patients (e.g., cN1–2 or pN1–2).15,16 However, their role in the treatment of pN0M0 ESCC patients, especially those with pT3N0M0 ESCC, is unknown.8 In this study, we investigated the impact of PORT, POCT, and other clinical factors on the LR, DM, and survival of pT3N0M0 ESCC patients.

Methods
Patient selection
The clinical data of all patients with thoracic ESCC pT3N0M0 (AJCC 2009), who underwent radical esophagectomy between January 2008 and December 2012 at the Fourth Hospital of Hebei Medical University in China, were retrospectively analyzed. The inclusion criteria were as follows: (1) survival of at least 3 months after radical R0 resection to minimize the impact of surgery-related deaths on the efficacy of postoperative adjuvant therapy, (2) a Karnofsky Performance Score (KPS) of at least 70 before surgery, (3) no preoperative neoadjuvant therapy, and (4) no history of other malignant tumors. The exclusion criteria were (1) non-squamous cell carcinoma of the esophagus, (2) R1/R2 resection, (3) preoperative neoadjuvant therapy, and (4) survival of less than 3 months after surgery, (5)
history of other malignant tumors, and (6) incomplete clinical, radiological, and follow-up data. This study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University. Written informed consent forms were signed and obtained from all recruited individuals.

**Surgery**

Before surgery, patients were examined with thoracic and abdominal computed tomography (CT), esophagogram, gastroscopy, and pathology to confirm ESCC. A left thoracotomy was the most common surgical approach for middle and lower thoracic EC. Radical surgical resection consisted of a transthoracic subtotal esophagectomy, including abdominal and mediastinal lymphadenectomy. A right thoracotomy was the most common surgical approach for upper thoracic EC. A gastric tube through the posterior mediastinal route was then used as a substitute for the resected esophagus to restore the continuity of the alimentary tract, and a cervical esophagogastric anastomosis was performed. Pathology and staging were conducted according to the 7th TNM cancer staging criteria.

**Postoperative therapies**

The postoperative therapies depended upon the stage of the disease, physical condition of the patient, economic status, and personal will of the patient. The demographic and clinical variables, including the preoperatively assigned upper, middle, or lower locations of thoracic ESCCs, were collected for analysis. All patients were categorized into three groups based on the treatment they received as follows: (1) surgery alone, (2) POCT alone, and (3) PORT (with or without sequential chemotherapy). The postoperative adjuvant therapies were administered within 3 months after surgery.

The administered chemotherapy drugs mainly consisted of cisplatin/nedaplatin, fluorouracil, and paclitaxel/docetaxel. Chemotherapy was initiated 3 to 4 weeks after surgery. The median number (range) of chemotherapy cycles prescribed was 3 (range 1–6).

All PORTs used three-dimensional conformal radiotherapy or intensity-modulated radiotherapy. None of the PORT patients received concurrent chemotherapy. The principle of postoperative clinical target volume delineation was to contour the lymphatic drainage regions depending on the location of the tumor as follows: (1) upper mediastinum, supraclavicular region, and lower neck for upper thoracic ESCC, (2) whole or partial mediastinum for middle thoracic ESCC, and (3) middle and lower mediastinum and the region around the left gastric artery for lower thoracic ESCC. All patients in this study had completed the prescribed PORT. The radiotherapy dosage delivery was 50 to 54 Gy/25 to 28 fractions (f), 1.8 to 2.0 Gy/f, and 5 f per week.

**Follow-up and outcomes**

All patients were followed up until death or 1 December 2016. The follow-up was scheduled every 3 months for 2 years, every 6 months for the next 3 years, and annually thereafter. Contrast-enhanced CT of the neck, thorax, and upper abdomen and routine blood and biochemistry investigations were performed at each follow-up visit. Ultrasonography of the neck and upper abdomen, a nuclear bone scan, gastric endoscopy, positron emission tomography, or cytologic puncture were performed, if indicated. Three outcomes were analyzed in this study: total recurrence (TR), LR, and DM. Specifically, TR was defined as any recurrence or metastasis during the
follow-up period. LR was defined as any locoregional tumor recurrence and/or metastatic lymph node at cervical, mediastinal, and upper abdomen regions defined by AJCC 2009. DM was defined as any event of recurrence or metastasis other than LR. Tumor recurrence and DM were diagnosed by imaging studies [any combination of ultrasound, CT, magnetic resonance imaging, single-photon emission CT, and positron emission tomography/CT (PET/CT)] with or without pathological confirmation by biopsy. Recurrence-free survival days were calculated from the date of surgery to the date of each analyzed outcome (TR, LR, and DM) or last follow-up date plus one.

**Statistical analysis**

A Kaplan–Meier curve and proportional hazard Cox regression model were used to determine the factors affecting tumor recurrence and compare events, such as overall survival (OS), among the subgroups. Logistic regression was used to analyze the association between clinical variables and binary outcomes. All statistical analysis was conducted with SPSS version 22.0. The statistical significance level was a two-sided p-value equal to 0.05.

**Results**

**Patient characteristics**

From 2008 to 2012, 2350 EC patients underwent esophagectomy at our hospital, of which 692 pT3N0M0 thoracic ESCC patients were included in this study. Their median age was 60 (range: 33–86) years, and 30% were women (Table 1). The surgery alone, POCT alone, and PORT subgroups included 278 (40%), 331(48%), and 83 (12%) patients, respectively. Two hundred and sixty-eight patients had mediastinal lymph nodes with a transverse diameter less than 1 cm (defined as “Med. large LN”) on CT imaging before surgery. Regarding the surgical approach, 611 (88%) patients underwent an esophagectomy via a left thoracotomy, and 679 (98%) patients received a two-field lymph node dissection (thorax and abdomen). The surgery of adhesions (defined as “Sur. Adhesions”) was recorded according to the difficulty in separating esophageal tumors from peripheral normal tissues or organs at surgery, which likely varied among surgeons. The median number of dissected lymph nodes was 9 (range: 1–27).

**Table 1. Patient and tumor characteristics.**

| Variable                  | Class          | N (%) |
|---------------------------|----------------|-------|
| Sex                       | Male           | 487 (70.4%) |
|                           | Female         | 205 (29.6%) |
| Age (years)               | ≤ 65           | 529 (76.4%) |
|                           | > 65           | 163 (23.6%) |
| Tumor location            | Upper          | 92 (13.3%) |
|                           | Middle         | 471 (60.1%) |
|                           | Lower          | 129 (26.6%) |
| Med. large LN             | No             | 424 (61.3%) |
|                           | Yes            | 268 (38.7%) |
| Tumor length (cm)         | ≤ 5            | 507 (73.3%) |
|                           | > 5            | 185 (26.7%) |
| Sur. adhesions            | No             | 33 (4.8%) |
|                           | Mild           | 279 (40.3%) |
|                           | Severe         | 303 (43.8%) |
|                           | Data missing   | 77 (11.1%) |
| LN dissected              | < 12           | 452 (65.3%) |
|                           | ≥ 12           | 240 (34.7%) |
| Tumor Diff.               | High/Moderate  | 612 (88.4%) |
|                           | Low            | 80 (11.6%) |
| Post. treatment           | Neither        | 278 (40.2%) |
|                           | PORT           | 83 (12%) |
|                           | POCT           | 331 (47.8%) |

Med., mediastinal; LN, lymph node; Sur., surgical; Diff., differentiation; Post., postoperative; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy.

The median follow-up period of the entire group was 53 months (range: 3–107).
Overall, the rates of TR, LR, and DM were 40%, 29.9%, and 19.1%, respectively. The 1-, 3-, and 5-year rates were 16.1%, 35.8%, and 41.0% for TR, 12.0%, 28.7%, and 32.1% for LR, and 6.4%, 16.8%, and 21.1% for DM, respectively. There were significant differences in the TR ($p = 0.018$), LR ($p = 0.016$), and DM ($p = 0.031$) rates of the three groups (Figure 1).

Univariate and multivariate Cox regression analysis showed that the tumor location, number of dissected lymph nodes, tumor differentiation, and POCT were significantly associated with TR, whereas the tumor location, number of dissected lymph nodes, PORT, and POCT were significantly associated with LR. Only tumor location and tumor differentiation were significantly associated with DM (Tables 2 and 3).

Statistically, POCT was associated with reduced TR [hazard ratio (HR) = 0.682; $p = 0.004$] and LR (HR = 0.665; $p = 0.008$), and PORT was associated with reduced LR (HR = 0.580; $p = 0.027$).

**Subgroup analysis based on tumor location**

We performed a subgroup analysis to determine the benefits of PORT and POCT among different subgroups of pT3N0M0 ESCC patients based on tumor location. We found that PORT was significantly associated with reduced TR ($p = 0.011$) and LR ($p = 0.029$) for upper ESCC alone and unexpectedly associated with higher DM for middle ESCC (HR = 1.944; $p = 0.043$). POCT was significantly associated with reduced TR ($p = 0.011$) and LR ($p = 0.038$) for middle ESCC (Table 4). No benefit of POCT or PORT was observed for lower ESCC compared with surgery alone.

**Association between postoperative therapy and the site of local recurrence**

LR was found to be distributed along cervical, mediastinum, and upper abdomen lymphatic drainage regions. We conducted univariate Cox regression to determine the impact of postoperative treatments on location-specific LR (Table 5). Compared with surgery alone, the addition of PORT and POCT reduced LR in the mediastinum ($p = 0.018$ and $p = 0.011$, respectively) but not in the cervix or upper abdomen.

**Discussion**

In this study, we observed that the TR rate among pT3N0M0 thoracic ESCC patients was as high as 40%. The LR and DM
Rates were 21% and 19%, respectively. Mediastinal LR accounted for 81% of LR. These results are similar to those reported by other Chinese studies.\(^9,11,12\) The current study demonstrated that tumor location was an independent risk factor for TR, LR, and DM. Upper thoracic ESCC had the highest LR rates, followed by middle and lower thoracic ESCC. This finding is in contrast to that reported by previous studies.\(^17,18\) We believe that this might be due to the difference in surgical approaches. In this study, most of our patients underwent two-field lymphadenectomy via a left thoracotomy. Many previous studies have suggested three-field lymph node dissection via a right thoracotomy, especially for upper or middle thoracic ESCC.

We found that the higher number of dissected lymph nodes was associated with higher TR among pT3N0M0 ESCC patients. In fact, the NCCN guidelines recommend that at least 15 lymph nodes should be dissected during radical esophagectomy for EC. Previous studies also support this recommendation.\(^19,20\) Greenstein et al.\(^19\) demonstrated that a high number of dissected lymph nodes was associated with an improved survival rate among pN0 ESCC patients. Dutkowski et al.\(^20\) suggested that at least 12 lymph nodes should be dissected to ensure the accuracy of N staging in EC patients. Although all patients had pN0 disease, most patients in this study did not receive PET/CT prior to surgery. Therefore, the possibility of unobserved metastatic lymph nodes cannot be

| Item                     | Group     | HR (95% CI)   | p   | HR (95% CI)   | p   | HR (95% CI)   | p   |
|--------------------------|-----------|---------------|-----|---------------|-----|---------------|-----|
| Gender                   | Male      | 1.161 (0.874–1.541) | 0.303 | 1.151 (0.850–1.559) | 0.364 | 1.162 (0.795–1.700) | 0.438 |
|                          | Female    | 1 |  | 1 |  | 1 |  |
| Ages                     | ≤ 65      | 1.040 (0.771–1.403) | 0.797 | 1.158 (0.848–1.583) | 0.356 | 1.093 (0.734–1.628) | 0.661 |
|                          | > 65      | 1 |  | 1 |  | 1 |  |
| Tumor location           | Upper     | 0.552 (0.406–0.750) | 0.000 | 0.605 (0.422–0.869) | 0.006 | 0.456 (0.297–0.699) | 0.000 |
|                          | Middle    | 0.337 (0.219–0.518) | 0.000 | 0.333 (0.199–0.557) | 0.000 | 0.343 (0.191–0.616) | 0.000 |
|                          | Lower     | 1.012 (0.781–1.311) | 0.931 | 1.111 (0.842–1.465) | 0.457 | 0.774 (0.539–1.111) | 0.165 |
| Tumor length             | ≤ 5 cm    | 1 |  | 1 |  | 1 |  |
|                          | > 5 cm    | 1 |  | 1 |  | 1 |  |
| Med. large LN            | No        | 1.177 (0.885–1.564) | 0.263 | 1.206 (0.891–1.634) | 0.226 | 1.394 (0.964–2.016) | 0.078 |
|                          | Yes       | 1 |  | 1 |  | 1 |  |
| LN dissected             | < 12      | 1.499 (1.132–1.985) | 0.005 | 1.452 (1.074–1.964) | 0.015 | 1.395 (0.959–2.027) | 0.081 |
|                          | ≥ 12      | 1 |  | 1 |  | 1 |  |
| Sur. adhesion            | No        | 1.517 (0.766–3.006) | 0.232 | 2.323 (0.942–5.727) | 0.067 | 2.008 (0.730–5.528) | 0.177 |
|                          | Slight    | 1 |  | 1 |  | 1 |  |
|                          | Severe    | 1.637 (0.829–3.232) | 0.155 | 2.357 (0.958–5.801) | 0.062 | 1.779 (0.645–4.908) | 0.266 |
|                          | No record | 1.664 (0.782–3.540) | 0.186 | 2.716 (1.043–7.076) | 0.041 | 1.527 (0.492–4.738) | 0.464 |
| Tumor Diff.              | Low       | 1.894 (1.348–2.661) | 0.000 | 1.350 (0.906–2.011) | 0.140 | 2.817 (1.882–4.216) | 0.000 |
|                          | Middle-high | 1 |  | 1 |  | 1 |  |
| Post. treatment          | Neither   | 0.999 (0.675–1.478) | 0.995 | 0.686 (0.428–1.099) | 0.117 | 1.407 (0.865–2.290) | 0.169 |
|                          | PORT      | 0.718 (0.547–0.943) | 0.017 | 0.669 (0.502–0.892) | 0.006 | 0.748 (0.514–1.089) | 0.130 |

TR, total recurrence; LR, locoregional recurrence; DM, distant metastasis. HR, hazard ratio; CI, confidence interval; LN, lymph node; Sur., surgical; Diff., differentiation; Post., postoperative; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy.
### Table 3. Multivariate Cox regression analysis of outcomes.

| Variable                  | Class | TR         |         |         | LR         |         |         | DM         |         |
|---------------------------|-------|------------|---------|---------|------------|---------|---------|------------|---------|
|                           |       | HR (95% CI)| p       |         | HR (95% CI)| p       |         | HR (95% CI)| p       |
| Sex                       | Female| 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | Male  | 1.196 (0.912–1.567) | 0.195 |         | 1.208 (0.883–1.652) | 0.238 |         | 1.236 (0.836–1.827) | 0.289 |
| Age (years)               | ≤ 65  | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | > 65  | 1.058 (0.796–1.407) | 0.696 |         | 1.106 (0.801–1.527) | 0.542 |         | 1.140 (0.754–1.723) | 0.534 |
| Tumor location            | Upper | 1.00       |         |         | 1.00       |         |         | <0.001     |         |
|                           | Middle| 0.604 (0.440–0.829) | 0.002 |         | 0.627 (0.433–0.908) | 0.014 |         | 0.551 (0.352–0.862) | 0.009 |
|                           | Lower | 0.362 (0.232–0.567) | <0.001 |         | 0.322 (0.189–0.549) | 0.000 |         | 0.434 (0.235–0.804) | 0.008 |
| Tumor length              | ≤ 5 cm| 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | > 5 cm| 1.189 (0.908–1.558) | 0.209 |         | 1.225 (0.905–1.660) | 0.189 |         | 0.886 (0.596–1.318) | 0.551 |
| Med. large LN             | No    | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | Yes   | 1.111 (0.852–1.449) | 0.435 |         | 1.212 (0.887–1.656) | 0.228 |         | 1.246 (0.847–1.832) | 0.263 |
| dissected LN              | < 12  | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | ≥ 12  | 0.724 (0.554–0.946) | 0.018 |         | 0.693 (0.509–0.945) | 0.021 |         | 0.799 (0.543–1.176) | 0.256 |
| Sur. adhesion             | No    | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | Slight| 1.624 (0.818–3.224) | 0.166 |         | 2.352 (0.947–5.840) | 0.065 |         | 1.619 (0.583–4.500) | 0.355 |
|                           | Severe| 1.456 (0.736–2.884) | 0.281 |         | 1.979 (0.800–4.898) | 0.140 |         | 1.436 (0.516–3.996) | 0.489 |
|                           | No record | 1.778 (0.844–3.744) | 0.130 |         | 2.749 (1.053–7.175) | 0.039 |         | 1.481 (0.475–4.618) | 0.498 |
| Tumor. Diff.              | High  | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | Neither | 1.684 (1.212–2.339) | 0.002 |         | 1.289 (0.855–1.944) | 0.226 |         | 2.431 (1.588–3.720) | 0.000 |
| Post. treatment           | Nordic | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|                           | PORT  | 0.784 (0.535–1.151) | 0.215 |         | 0.580 (0.358–0.941) | 0.027 |         | 1.096 (0.658–1.827) | 0.724 |
|                           | POCT  | 0.682 (0.524–0.886) | 0.004 |         | 0.665 (0.493–0.898) | 0.008 |         | 0.702 (0.476–1.036) | 0.075 |

TR, total recurrence; LR, locoregional recurrence; DM, distant metastasis. HR, hazard ratio; CI, confidence interval; LN, lymph node; Sur., surgical; Diff., differentiation; Post., postoperative; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy.

### Table 4. Univariate logistic regression by tumor location.

| Location | Treatment | TR         |         |         | LR         |         |         | DM         |         |
|----------|-----------|------------|---------|---------|------------|---------|---------|------------|---------|
|          |           | HR (95% CI)| p       |         | HR (95% CI)| p       |         | HR (95% CI)| p       |
| Upper    | Neither   | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|          | PORT      | 0.147 (0.033–0.649) | 0.011 |         | 0.091 (0.011–0.780) | 0.029 |         | 0.467 (0.108–2.020) | 0.308 |
|          | POCT      | 0.528 (0.209–1.331) | 0.176 |         | 0.629 (0.285–1.682) | 0.417 |         | 0.412 (0.156–1.084) | 0.072 |
| Middle   | Neither   | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|          | PORT      | 1.118 (0.637–1.962) | 0.697 |         | 0.702 (0.381–1.292) | 0.255 |         | 1.944 (1.022–3.698) | 0.043 |
|          | POCT      | 0.594 (0.397–0.889) | 0.011 |         | 0.640 (0.420–0.976) | 0.038 |         | 0.737 (0.433–1.254) | 0.261 |
| Lower    | Neither   | 1.00       |         |         | 1.00       |         |         | 1.00       |         |
|          | PORT      | 0.750 (0.077–7.283) | 0.804 |         | 0.917 (0.094–8.983) | 0.940 |         | –          | –       |
|          | POCT      | 1.250 (0.562–2.778) | 0.584 |         | 0.708 (0.285–1.754) | 0.455 |         | 1.970 (0.696–5.575) | 0.202 |

TR, total recurrence; LR, locoregional recurrence; DM, distant metastasis. HR, hazard ratio; CI, confidence interval; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy. Covariates included all variables listed in Table 2 except for the tumor location.
ruled out. The impact of this possible scenario on the long-term outcomes in this study is not known.

The present study found that poorly differentiated ESCC had a significantly higher risk of TR and DM. Similar results were reported in other studies. The study did not find any association between tumor differentiation and LR rates.

Most importantly, this study found that PORT was associated with significantly reduced TR and LR in patients with upper thoracic pT3N0M0 ESCC. Moreover, the incidence of LR after PORT was lower for the mediastinal region. Liu et al. found that PORT for the supraclavicular, upper mediastinal lymphatic drainage regions, and tumor bed could reduce intrathoracic lymph node recurrence in pT2–3N0M0 ESCC patients. Chen et al. concluded that PORT with T field irradiation was associated with reduced tumor bed LR without any improvement in the OS of pT1–4N0M0 ESCC patients, and many other studies have suggested that PORT could significantly improve OS and disease-free survival (DFS) among pT3N0M0 thoracic ESCC patients.

In addition, this study showed that POCT was associated with reduced LR in the mediastinum. A meta-analysis by Zhang et al. suggested that POCT could increase the 3-year DFS but not 3-year OS in stage III–IV ESCC patients. However, recent studies have shown that POCT could improve OS and DFS among pN+ patients. Because these studies included different populations of ESCC patients, further prospective studies are needed to determine the exact roles of PORT and POCT in the treatment of pN0 ESCC.

This study has several limitations. First, it was a retrospective single-center study, and the patients were included based on the selection criteria. Therefore, the possibility of selection bias cannot be excluded, despite the use of multivariate analysis. Second, in this study, 88% of patients underwent esophagectomy via a left thoracic approach, and 98% of patients received two-field lymphadenectomy. The impact of different surgical approaches was not considered in the analysis. Thus, the results likely cannot be extrapolated to those using alternative approaches. Indeed, dissection of the upper mediastinal lymph nodes via the left thoracic approach was inadequate, and the number of lymph nodes retrieved was significantly lower than that recommended by the NCCN guidelines. Moreover, most of the study patients did not receive PET/CT prior to or after surgery; thus, some patients with undetected lymph node metastasis may

| Treatment | LR at cervical HR (95% CI) | p | LR at mediastinum HR (95% CI) | p | LR at upper-abdomen HR (95% CI) | p |
|-----------|---------------------------|---|-------------------------------|---|-------------------------------|---|
| No        | 1.00                      |   | 1.00                          |   | 1.00                          |   |
| PORT      | 1.005 (0.390–2.592)       | 0.991 | 0.469 (0.250–0.879) | 0.018 | 1.691 (0.304–9.402) | 0.548 |
| POCT      | 0.485 (0.233–1.011)       | 0.054 | 0.619 (0.429–0.895) | 0.011 | 2.800 (0.903–8.688) | 0.075 |

LR, locoregional recurrence; HR, hazard ratio; CI, confidence interval; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy.
have benefitted from postoperative adjuvant therapy leading to improved survival in these patients. However, several Chinese studies have shown that the OS for middle and lower thoracic EC patients treated using Sweet and Ivor Lewis techniques are similar.\(^{27-30}\) Ma Q et al.\(^{29}\) showed that the 3- and 5-year cancer-specific survival rates and OS were higher with the left transthoracic approach than the right transthoracic approach for pN\(_0\) ESCC patients. Ma J et al.\(^{30}\) reported that there was no significant difference in LR or distant recurrence with the Ivor Lewis or Sweet approach. Compared with the Ivor Lewis approach, the Sweet approach has a shorter operative time, less blood loss, a lower incidence of transfusion, and reduced postoperative complications.\(^{27-30}\)

Third, the individual dosages of PORT and POCT were slightly different and not analyzed in detail. However, because conducting randomized controlled trials on POCT and PORT aimed at improving the survival of pT3N\(_0\)M\(_0\) ESCC in our institution (or any institution in China) is difficult, we believe that the results of large sample-size studies from one or more high-volume institutions may be valuable. Prospective single-arm clinical studies can also partially verify the conclusions of this study.

In summary, LR was the main cause of treatment failure in pT3N\(_0\)M\(_0\) thoracic ESCC patients after two-field dissection. Tumor location and the number of dissected lymph nodes were significantly associated with LR. PORT could decrease LR in the upper third of the thoracic cavity in pT3N\(_0\)M\(_0\) patients, and POCT could reduce LR in the middle thoracic segment in pT3N\(_0\)M\(_0\) patients. Future studies are needed to validate our findings.

**Acknowledgments**

The authors would like to thank all clinical staff who provided years of care for the patients enrolled in this study.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Yu-Xiang Wang https://orcid.org/0000-0002-1049-8469

**References**

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2. Zhang HZ, Jin GF and Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer 2012; 31: 281–286.
3. Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries. Thorac Cancer 2016; 7: 232–237.
4. Hsu PK, Wang BY, Huang CS, et al. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg 2011; 15: 558–565.
5. Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
6. Huang Y, Wang H, Luo G, et al. A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. Int J Surg 2017; 38: 41–47.
7. Guo XF, Mao T, Gu ZT, et al. Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma. J Cardiothorac Surg 2014; 9: 150.
8. Liu X, Zhang WC, Yu SF, et al. Patterns of failure after radical surgery among patients...
with stage T2-3N0M0 esophageal squamous cell carcinoma potential value of postoperative radiotherapy. *Chin J Radiat Oncol* 2015; 24: 19–24.

9. Wang Y, Wang L, Yang Q, et al. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy]. *Zhonghua Zhong Liu Za Zhi* 2016; 38: 48–54.

10. Li CL, Zhang FL, Wang YD, et al. Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer. *Oncol Lett* 2013; 5: 355–359.

11. Shen WB, Gao HM, Zhu SC, et al. Analysis of postoperative failure in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma and consideration of postoperative radiotherapy. *Chin J Radiat Oncol* 2017 26: 394–399.

12. Wu H, Liu C, Xu M, et al. Prognostic value of the number of negative lymph nodes in esophageal carcinoma without lymphatic metastasis. *Thorac Cancer* 2018; 9: 1129–1135.

13. Wang YX, Dong SL, He M, et al. Analysis of risk factors of recurrence of pT1-3N0M0 esophageal squamous cell carcinoma after two-field esophagectomy. *Chin J Radiat Oncol* 2018 27: 145–149.

14. Zhang HD, Shang XB, Zhu XL, et al. Impact of the number of lymph node examined on the prognosis of esophageal squamous cell carcinoma. *Chin J Dig Surg* 2018; 17: 817–824.

15. Chen SB, Weng HR, Wang G, et al. The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol* 2016; 142: 277–286.

16. Shridhar R, Weber J, Hoffe SE, et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. *J Gastrointest Surg* 2013; 17: 1339–1345.

17. Tanaka H, Ohira M, Kubo N, et al. Association of location of lymph node metastases with postoperative recurrence of esophageal squamous cell carcinoma. *Anticancer Res* 2012; 32: 3421–3426.

18. Smit JK, Pultrum BB, Van Dullemen HM, et al. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. *Am J Surg* 2010; 200: 446–453.

19. Greenstein AJ, Little VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. *Cancer* 2008; 112: 1239–1246.

20. Dutkowski P, Hommel G, Bottger T, et al. How many lymph nodes are needed for an accurate pN classification in esophageal cancer? Evidence for a new threshold value. *Hepatogastroenterology* 2002; 49: 176–180.

21. Sun Z, Wang Z, Liu XY, et al. A clinical analysis of risk factor with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis Esophagectomy. *Chin J Thorac Cardiovasc Surg* 2011; 27: 108–111.

22. Chen JQ, Pan JJ, Chen MQ, et al. Postoperative prophylactic radiotherapy for N0 esophageal squamous cell carcinoma. *Chin J Radio Oncol* 2009; 18: 261–264.

23. Yang Q, Wang YX, He M, et al. Factors affecting on long-time survival in patients with stage III thoracic esophageal carcinoma after esophagectomy. *Chin J Oncol* 2016; 38: 530–537.

24. Zhang SS, Yang H, Xie X, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies. *Dis Esophagus* 2014; 27: 574–584.

25. Lyu X, Huang J, Mao Y, et al. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? *J Surg Oncol* 2014; 110: 864–868.

26. Duan J, Deng T, Ying G, et al. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy. *Jpn J Clin Oncol* 2016; 46: 336–343.
27. Feng Y, Wu N, Yan S, et al. Comparison of Ivor Lewis esophagectomy and Sweet esophagectomy for the treatment of middle-lower esophageal squamous cell carcinoma. *J Thorac Dis* 2019; 11: 3584–3592.

28. Wang J, Wei N, Jiang N, et al. Comparison of Ivor-Lewis versus Sweet procedure for middle and lower thoracic esophageal squamous cell carcinoma A STROBE compliant study. *Medicine (Baltimore)* 2019; 98: e14416.

29. Ma Q, Liu W, Long H, et al. Right versus left transthoracic approach for lymph node-negative esophageal squamous cell carcinoma. *J Cardiothorac Surg* 2015; 10: 123.

30. Ma J, Zhan C, Wang L, et al. The sweet approach is still worthwhile in modern esophagectomy. *Ann Thorac Surg* 2014; 97: 1728–1733.